ClinicalTrials.gg
TerminatedNCT04500899Updated Nov 16, 2026Results posted

Use of Phenylephrine for Assessment of Mitral Regurgitation Severity

A Phase 1/2 interventional study of Phenylephrine Hydrochloride in Mitral Regurgitation, sponsored by Montefiore Medical Center. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Montefiore Medical Center · Phase 1/2, Interventional, and Diagnostic

How we know

Why this study was terminated
IRB Approval lapsed, study being terminated due to slow enrollment
Updated Nov 16, 2026Now TerminatedResults posted+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 118 studies in Mitral Valve Insufficiency with a site in United States — 33 open to participants now, 53 under way, none of them phase 3. Mitral Valve Insufficiency · United States.

Enrollment
75th of 81
8 · median 60
Started
2020
with 10 others
Phase 1/2
3 of 118
none open now
Registered
80th of 118
by date

Among the 118 studies in Mitral Valve Insufficiency with a site in United States, this one is the 75th largest by enrollment of the 81 interventional ones that give a count, is one of 11 that started in 2020, is one of 3 in phase 1/2, and was the 80th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

33 of the 118 studies in Mitral Valve Insufficiency with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Mitral Valve Insufficiency with a site in United States, or all of them as a file.
02

Study summary

The study proposes to develop a phenylephrine protocol to be used during transesophageal echocardiography (TEE), whereby intravenous phenylephrine would be used to increase afterload with the intent to mimic the awake hemodynamic profile and variation that occurs with normal physical activity. The expectation is to see changes in severity of Mitral Regurgitation (MR) grade with increasing afterload, which in turn can provide more accurate quantification of MR severity to assist in clinical decision making.

Read the detailed description

Routine echocardiography which is used to assess the severity of mitral regurgitation, sometimes underestimates the severity of mitral regurgitation, due to hemodynamic variations that occurs with normal physical activity and under the effect of sedation which is used to perform transesophageal echocardiography. By using phenylephrine during transesophageal echocardiography, the study intends to offset the hemodynamic variation that occurs with sedation and better assess the severity of mitral regurgitation, which would further assist in clinical decision-making regarding treatment. The goal of this study is to compare the severity of mitral regurgitation grade before and after the administration of phenylephrine during transesophageal echocardiography and to demonstrate a 25% increase in severity of mitral regurgitation grade compared to the baseline conditions, following the administration of phenylephrine.

03

Conditions studied

  • Mitral Regurgitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 18 years or older with MR on baseline echocardiographic evaluation who are scheduled to undergo TEE for further evaluation of mitral regurgitation.

Exclusion criteria

Exclusion Criteria:

  • The following patients will be excluded from the study:

    1. Patients who are not clinically eligible for TEE.
    2. Patients with to esophageal intubation.
    3. Patients with hemodynamic instability.
    4. Patients with acute decompensated heart failure (HF).
    5. Patients with un-revascularized severe coronary artery disease (triple vessel or left main disease).
    6. Patients with ongoing unstable angina or ongoing myocardial infarction (MI)
    7. Patients with significant arrhythmias including atrial fibrillation.
    8. Patients with uncontrolled hypertension (BP ≥ 150/90 mmHg).
    9. Patients with preexisting bradycardia (HR \< 50) and heart blocks.
    10. Patients with severe symptomatic peripheral vascular disease.
    11. Patients with severe pulmonary hypertension (estimated systolic pulmonary arterial pressure sPAP ≥ 60mm Hg).
    12. Patients who are at high risk for intracranial bleeding such as patients with previous strokes, (TIA) and vascular malformations.
    13. Additionally, patients with mean arterial blood pressure MAP > 100 mmHg during TEE and those with severe MR, effective regurgitant orifice area (ERO > 39cm2) on baseline TEE evaluation will not be given phenylephrine and excluded from the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Phenylephrine Hydrochloride

    Phenylephrine is available as phenylephrine hydrochloride injection, 10 mg/mL in 1 mL vial. For intravascular bolus administration, the investigators will prepare a solution containing 100 mcg/mL of phenylephrine hydrochloride, by withdrawing 10 mg (1ml of 10mg/mL) of phenylephrine injection and diluting with 99 mL of 5% dextrose injection or 0.9% sodium chloride injection. A 20 mcg intravenous test dose of phenylephrine will be administered by the cardiologist performing the TEE. BP will be monitored after each bolus of phenylephrine. Subsequent phenylephrine injections will then be administered in 50 mcg aliquots every 10-15 minutes, instead of 40 mcg, until the mean arterial blood pressure (MAP) increases by ≥ 20 mm Hg from the baseline MAP, making sure not to exceed a MAP of 100 mmHg. Once a desired blood pressure has been achieved and maintained, echocardiographic evaluation of mitral regurgitation would be performed.

    Drug: Phenylephrine Hydrochloride

Interventions

  • DrugPhenylephrineStudies of PhenylephrinePhenylephrine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Phenylephrine hydrochloride injection (10 mg/mL) was diluted to 100 mcg/mL (10 mg in 99 mL of 5% dextrose or 0.9% sodium chloride) for intravenous bolus administration. A 20 mcg test dose was administered by the cardiologist performing the TEE, followed by 50 mcg boluses every 10-15 minutes until mean arterial pressure (MAP) increased by ≥20 mmHg from baseline MAP, without exceeding a MAP of 100 mmHg. Blood pressure was monitored after each bolus.

06

What researchers measure

Primary outcomes

  1. Number of Patients With Greater Than 25% Increase in Mitral Regurgitant Volume (RVol)

    The purpose of this study is to compare the echocardiographic parameters of MR grade before and after the use of phenylephrine during transesophageal echocardiography (TEE) and to document a change in echocardiographic parameters of MR grade after the use of phenylephrine. RVol is a measure of volume overload and represents the total volume of blood leaking backward into the left atria each beat. RVol will be quantitatively graded by the Proximal Isovelocity Surface Area (PISA) method on TEE, before and after phenylephrine administration. Participants were counted if post-phenylephrine RVol increased by greater than 25% from pre-phenylephrine RVol.

    Time frame: Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours

  2. Change in Effective Regurgitant Orifice Area (ERO)

    The purpose of this study is to compare the echocardiographic parameters of MR grade before and after the use of phenylephrine during transesophageal echocardiography (TEE) and to document a change in echocardiographic parameters of MR grade after the use of phenylephrine. ERO reflects the size of the regurgitant lesion and measures lesion severity. ERO is measured on TEE and graded using the PISA method (regurgitant flow = 2 × π × r² × aliasing velocity), before and after phenylephrine administration. Change is calculated as post-phenylephrine ERO minus pre-phenylephrine ERO and reported in square centimeters (cm²). Positive values indicate an increase in ERO area.

    Time frame: Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours

  3. Change in 3D Vena Contracta Diameter

    The purpose of this study is to compare the echocardiographic parameters of MR grade before and after the use of phenylephrine during transesophageal echocardiography (TEE) and to document a change in echocardiographic parameters of MR grade after the use of phenylephrine administration. Change in vena contracta diameter, assessed before and after phenylephrine, will be measured in millimeters (mm) by 3D TEE. Change is calculated as post-phenylephrine value minus pre-phenylephrine value and reported in millimeters (mm). Positive values indicate an increase in vena contracta diameter.

    Time frame: Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours

  4. Change in Visual Mitral Regurgitation Grade

    The purpose of this study is to compare the echocardiographic parameters of MR grade before and after the use of phenylephrine during transesophageal echocardiography (TEE) and to document a change in echocardiographic parameters of MR grade after the use of phenylephrine administration. Semi-quantitative visual MR is assessed during TEE before and after phenylephrine and graded on a 4-point scale ranging from 1 ("mild") to 4 ("severe"), integrating PISA-derived ERO/RVol and 3D vena contracta. Change calculated as post-phenylephrine grade minus pre-phenylephrine grade. Positive values indicate worsening MR grade.

    Time frame: Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours

07

Results

Posted Nov 16, 2026
Limitations and caveats
The study was terminated early with 8 of a planned 35 participants enrolled. 5 participants were excluded after baseline TEE because baseline mitral regurgitation was too severe, and one discontinued after an adverse reaction to the phenylephrine test dose. Outcome data are, therefore, available for only 2 participants. Results are descriptive only, and no inferential analyses were performed. The small sample size precludes conclusions about the effect of phenylephrine on MR severity assessment.

Participant flow

Eligibility depended partly on the severity of Mitral Regurgitation (MR) seen on the baseline Transesophageal Echocardiogram (TEE).

Participant flow — Overall Study
MilestonePhenylephrine Hydrochloride
Started8
Completed2
Not completed6
Withdrew: Baseline mr too severe on baseline tee5
Withdrew: Adverse event1

Outcome measures

PrimaryNumber of Patients With Greater Than 25% Increase in Mitral Regurgitant Volume (RVol)

The purpose of this study is to compare the echocardiographic parameters of MR grade before and after the use of phenylephrine during transesophageal echocardiography (TEE) and to document a change in echocardiographic parameters of MR grade after the use of phenylephrine. RVol is a measure of volume overload and represents the total volume of blood leaking backward into the left atria each beat. RVol will be quantitatively graded by the Proximal Isovelocity Surface Area (PISA) method on TEE, before and after phenylephrine administration. Participants were counted if post-phenylephrine RVol increased by greater than 25% from pre-phenylephrine RVol.

Time frame:
Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours
Reported as:
Count of participants · Participants
Number of Patients With Greater Than 25% Increase in Mitral Regurgitant Volume (RVol)
ParticipantsPhenylephrine Hydrochloride
Number of Patients With Greater Than 25% Increase in Mitral Regurgitant Volume (RVol)2
PrimaryChange in Effective Regurgitant Orifice Area (ERO)

The purpose of this study is to compare the echocardiographic parameters of MR grade before and after the use of phenylephrine during transesophageal echocardiography (TEE) and to document a change in echocardiographic parameters of MR grade after the use of phenylephrine. ERO reflects the size of the regurgitant lesion and measures lesion severity. ERO is measured on TEE and graded using the PISA method (regurgitant flow = 2 × π × r² × aliasing velocity), before and after phenylephrine administration. Change is calculated as post-phenylephrine ERO minus pre-phenylephrine ERO and reported in square centimeters (cm²). Positive values indicate an increase in ERO area.

Time frame:
Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours
Reported as:
Mean · square centimeters (cm²)
Change in Effective Regurgitant Orifice Area (ERO)
square centimeters (cm²)Phenylephrine Hydrochloride
Change in Effective Regurgitant Orifice Area (ERO)0.08 ± 0.00
PrimaryChange in 3D Vena Contracta Diameter

The purpose of this study is to compare the echocardiographic parameters of MR grade before and after the use of phenylephrine during transesophageal echocardiography (TEE) and to document a change in echocardiographic parameters of MR grade after the use of phenylephrine administration. Change in vena contracta diameter, assessed before and after phenylephrine, will be measured in millimeters (mm) by 3D TEE. Change is calculated as post-phenylephrine value minus pre-phenylephrine value and reported in millimeters (mm). Positive values indicate an increase in vena contracta diameter.

Time frame:
Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours
Reported as:
Mean · millimeters
Change in 3D Vena Contracta Diameter
millimetersPhenylephrine Hydrochloride
Change in 3D Vena Contracta Diameter1.0 ± 0.5
PrimaryChange in Visual Mitral Regurgitation Grade

The purpose of this study is to compare the echocardiographic parameters of MR grade before and after the use of phenylephrine during transesophageal echocardiography (TEE) and to document a change in echocardiographic parameters of MR grade after the use of phenylephrine administration. Semi-quantitative visual MR is assessed during TEE before and after phenylephrine and graded on a 4-point scale ranging from 1 ("mild") to 4 ("severe"), integrating PISA-derived ERO/RVol and 3D vena contracta. Change calculated as post-phenylephrine grade minus pre-phenylephrine grade. Positive values indicate worsening MR grade.

Time frame:
Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours
Reported as:
Mean · units on a scale
Change in Visual Mitral Regurgitation Grade
units on a scalePhenylephrine Hydrochloride
Change in Visual Mitral Regurgitation Grade1.0 ± 0.0
Post-hocChange in Mitral Regurgitant Volume (RVol)

Mitral regurgitant volume per beat measured by the PISA method during transesophageal echocardiography, before and after phenylephrine administration. Change calculated as post-phenylephrine RVol minus pre-phenylephrine RVol. Positive values indicate an increase in regurgitant volume.

Time frame:
Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours
Reported as:
Mean · milliliters
Change in Mitral Regurgitant Volume (RVol)
millilitersPhenylephrine Hydrochloride
Change in Mitral Regurgitant Volume (RVol)24 ± 9

Adverse events

Collected over From start of the study TEE procedure through up to 2 hours after phenylephrine administration (duration of study participation). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phenylephrine Hydrochloride0/8 (0%)0/8 (0%)1/8 (12.5%)
Most frequent other events
Most frequent other events
EventPhenylephrine Hydrochloride
Severe HypertensionVascular disorders1/8
BradycardiaCardiac disorders1/8

Baseline characteristics

Baseline data provided for all eight enrolled participants who signed informed consent. Race and ethnicity were recorded as a single combined category.

Age, Continuous
Age, Continuous(years)Phenylephrine Hydrochloride
Mean68 ± 12
Sex: Female, Male
Sex: Female, Male(Participants)Phenylephrine Hydrochloride
Female5
Male3
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phenylephrine Hydrochloride
Black4
Hispanic3
Undetermined1
Region of Enrollment
Region of Enrollment(participants)Phenylephrine Hydrochloride
United States8
08

Study locations

1 site
09

References and documents

Publications

  • Carabello BA. The current therapy for mitral regurgitation. J Am Coll Cardiol. 2008 Jul 29;52(5):319-26. doi: 10.1016/j.jacc.2008.02.084. PubMed 18652937 ↗
  • Lehmann KG, Francis CK, Dodge HT. Mitral regurgitation in early myocardial infarction. Incidence, clinical detection, and prognostic implications. TIMI Study Group. Ann Intern Med. 1992 Jul 1;117(1):10-7. doi: 10.7326/0003-4819-117-1-10. PubMed 1596042 ↗
  • Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL, Lehman B, Benjamin EJ. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999 Mar 15;83(6):897-902. doi: 10.1016/s0002-9149(98)01064-9. PubMed 10190406 ↗
  • Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, Jneid H, Mack MJ, McLeod CJ, O'Gara PT, Rigolin VH, Sundt TM 3rd, Thompson A. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017 Jul 11;70(2):252-289. doi: 10.1016/j.jacc.2017.03.011. Epub 2017 Mar 15. No abstract available. PubMed 28315732 ↗
  • Shiran A, Merdler A, Ismir E, Ammar R, Zlotnick AY, Aravot D, Lazarovici H, Zisman E, Pizov R, Lewis BS. Intraoperative transesophageal echocardiography using a quantitative dynamic loading test for the evaluation of ischemic mitral regurgitation. J Am Soc Echocardiogr. 2007 Jun;20(6):690-7. doi: 10.1016/j.echo.2006.11.004. PubMed 17543738 ↗
  • Sanfilippo F, Johnson C, Bellavia D, Morsolini M, Romano G, Santonocito C, Centineo L, Pastore F, Pilato M, Arcadipane A. Mitral Regurgitation Grading in the Operating Room: A Systematic Review and Meta-analysis Comparing Preoperative and Intraoperative Assessments During Cardiac Surgery. J Cardiothorac Vasc Anesth. 2017 Oct;31(5):1681-1691. doi: 10.1053/j.jvca.2017.02.046. Epub 2017 Feb 13. PubMed 28506541 ↗
  • Kolev N, Brase R, Wolner E, Zimpfer M. Quantification of mitral regurgitant flow using proximal isovelocity surface area method: a transesophageal echocardiography perioperative study. J Cardiothorac Vasc Anesth. 1998 Feb;12(1):22-6. doi: 10.1016/s1053-0770(98)90050-7. PubMed 9509352 ↗
  • Recusani F, Bargiggia GS, Yoganathan AP, Raisaro A, Valdes-Cruz LM, Sung HW, Bertucci C, Gallati M, Moises VA, Simpson IA, et al. A new method for quantification of regurgitant flow rate using color Doppler flow imaging of the flow convergence region proximal to a discrete orifice. An in vitro study. Circulation. 1991 Feb;83(2):594-604. doi: 10.1161/01.cir.83.2.594. PubMed 1991377 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Dec 2020 to primary completion in Jul 2022, 19 months.

Results were first posted in Nov 2026, 4 years 3 months after primary completion.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Jun 2026 → Jul 2022 and completion Jun 2026 → Jul 2022.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2020
First posted
Aug 5, 2020
StartActual
Dec 1, 2020
Primary completionActual
Jul 19, 2022was Jun 2026
CompletionActual
Jul 19, 2022was Jun 2026
Results first posted
Nov 16, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated IRB Approval lapsed, study being terminated due to slow enrollment
changed Nov 16, 2026
Results
Results posted
posted Nov 16, 2026
Primary completion
Jun 2026→Jul 19, 2022 (actual)
Nov 16, 2026
Study completion
Jun 2026→Jul 19, 2022 (actual)
Nov 16, 2026
Enrollment
35 (estimated)→8 (actual)
Nov 16, 2026
Interventions
Added Drug: Phenylephrine Hydrochloride; removed Drug: Mydfrin. Arms added: Phenylephrine Hydrochloride; arms removed: Mydfrin
Nov 16, 2026
Primary outcomes
1 edited, 3 added
What changed in the outcomes
  • EditedThe percentageNumber of patients with greater thanPatients With Greater Than 25% increaseIncrease in MR regurgitant volumeMitral Regurgitant Volume (RvolRVol) after the use of phenylephrine during transesophageal echocardiography.Time frame: Before and after phenylephrine administration during transesophageal echocardiography, approximately 40 minutes → Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours
  • AddedChange in Effective Regurgitant Orifice Area (ERO)Time frame: Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours
  • AddedChange in 3D Vena Contracta DiameterTime frame: Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours
  • AddedChange in Visual Mitral Regurgitation GradeTime frame: Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours
Nov 16, 2026
Documents
Show all 1 update
  1. Nov 16, 2026
    Recruiting→Terminated
    Why stopped IRB Approval lapsed, study being terminated due to slow enrollment
    Results posted
    Primary completion Jun 2026→Jul 19, 2022 (now actual)
    Study completion Jun 2026→Jul 19, 2022 (now actual)
    Enrollment 35 (estimated)→8 (actual)
    Primary outcomes 1 edited, 3 added
    What changed in the outcomes
    • EditedThe percentageNumber of patients with greater thanPatients With Greater Than 25% increaseIncrease in MR regurgitant volumeMitral Regurgitant Volume (RvolRVol) after the use of phenylephrine during transesophageal echocardiography.Time frame: Before and after phenylephrine administration during transesophageal echocardiography, approximately 40 minutes → Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours
    • AddedChange in Effective Regurgitant Orifice Area (ERO)Time frame: Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours
    • AddedChange in 3D Vena Contracta DiameterTime frame: Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours
    • AddedChange in Visual Mitral Regurgitation GradeTime frame: Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours
    Interventions Added Drug: Phenylephrine Hydrochloride; removed Drug: Mydfrin. Arms added: Phenylephrine Hydrochloride; arms removed: Mydfrin
    + 5 other changes: verification date, description, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04500899
Responsible party
Sponsor
First posted
Aug 5, 2020
Start date
Dec 1, 2020
Primary completion
Jul 19, 2022
Completion
Jul 19, 2022
Results posted
Nov 16, 2026
Last update
Nov 16, 2026

Study contacts

Mario Garcia, MD
principal investigator · Montefiore Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Phenylephrine

Start the discussion